Brexanolone - Sage Therapeutics
Alternative Names: Allopregnanolone/sulfobutylether‐beta‐cyclodextrin; brexanolone IV; SAGE-547; SGE-102; ZULRESSOLatest Information Update: 08 Jan 2024
At a glance
- Originator University of California, Davis
- Developer SAGE Therapeutics
- Class Antidepressants; Antiepileptic drugs; Small molecules; Steroids
- Mechanism of Action GABA A receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Postnatal depression
- Phase II Tinnitus
- Discontinued Essential tremor; Major depressive disorder; SARS-CoV-2 acute respiratory disease; Status epilepticus
Most Recent Events
- 21 Nov 2023 Sage Therapeutics completes a phase II trial in Tinnitus in USA (IV) (NCT05645432)
- 10 May 2023 Phase-II clinical trials in Tinnitus in USA (IV) (NCT05645432)
- 09 Dec 2022 Sage Therapeutics plans a phase II trial for Tinnitus in March 2023 (IV), (NCT05645432)